Is CVS Health (CVS) Pricing Reflect Its Integrated Healthcare Potential After Recent Share Rebound

• Wondering if CVS Health at around US$78.84 is giving you fair value for the risk you are taking, or if the current price is leaving something on the table?
• The stock has a 7.3% return over the past 7 days and 3.3% over the last month, while the year to date return sits at a 1.6% decline and the 1 year return is 18.7%.
• Recent headlines have focused on CVS Health's positioning as a major integrated healthcare player and its ongoing efforts to balance its retail, pharmacy benefit, and health services operations. This mix of businesses is often front of mind for investors when stock price moves catch attention.
• CVS Health currently holds a valuation score of 3/6. The sections ahead will walk through how different valuation methods frame that result, while also pointing to a broader way to think about what the market is pricing in by the end of the article.

CVS Health delivered 18.7% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Approach 1: CVS Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash CVS Health is expected to generate in the future, then discounts those cash flows back to today to estimate what the business might be worth right now.

For CVS Health, the latest twelve month free cash flow sits at about $7.6b. Analysts provide cash flow estimates out to 2030, with Simply Wall St extrapolating beyond that using its 2 Stage Free Cash Flow to Equity model. Within this framework, projected free cash flow for 2030 is $14.0b, with intermediate years such as 2026 and 2027 projected at $8.4b and $10.2b respectively, all in dollars.

When these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $273.77 per share. Against a current share price around $78.84, this implies CVS Health trades at a roughly 71.2% discount to this DCF estimate, indicating that the market price is significantly below this particular model-based valuation of the company’s cash flows.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CVS Health is undervalued by 71.2%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CVS Health.

Approach 2: CVS Health Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you are paying for a share to the earnings that support that price. A higher or lower P/E often reflects what the market is implying about future growth and the level of risk investors are willing to accept.

In general, stronger growth prospects or lower perceived risk can support a higher P/E, while slower expected growth or higher risk tend to align with a lower, more conservative P/E. That context matters when you compare one stock's multiple with others in the same space.

CVS Health currently trades on a P/E of 57.15x, compared with a Healthcare industry average of about 22.60x and a peer group average of 18.53x. Simply Wall St's Fair Ratio for CVS Health is 39.45x, which is its proprietary view of what a reasonable P/E could be, given factors such as earnings growth, profit margins, industry, market cap and stock specific risks.

Because the Fair Ratio incorporates these company specific drivers, it can be more informative than a simple comparison to peers or the broad industry. With the current P/E of 57.15x sitting above the Fair Ratio of 39.45x, the shares screen as overvalued on this multiple framework.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your CVS Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives come in as your way to connect a clear story about CVS Health with specific assumptions for future revenue, earnings and margins, then link that to a fair value that can be compared with the current share price.

On Simply Wall St's Community page, Narratives let you set out your view of CVS Health in plain language, tie it to a forecast and fair value, and then see instantly whether that view suggests the shares look expensive or cheap at today’s price, with the model updating automatically when new earnings, news or guidance arrive.

For example, one CVS Health Narrative on the platform currently anchors to a fair value around US$62 per share with more moderate growth assumptions. Another builds a case for fair value closer to US$104 based on different expectations for revenue, margins and the company’s integrated healthcare model. The gap between those viewpoints is what helps you decide which story aligns better with your own expectations before you act.

For CVS Health however we will make it really easy for you with previews of two leading CVS Health Narratives:

🐂 CVS Health Bull Case

Fair value: US$104.01 per share

Implied discount to this narrative: about 24% below fair value at the recent US$78.84 price

Revenue growth assumption: 18.02%

• This bullish narrative focuses on CVS Health as an integrated healthcare platform, linking insurance, pharmacy benefits, retail locations and care delivery into one model.
• It builds in relatively strong revenue growth and a lower assumed discount rate, which together support a higher fair value estimate than the current share price.
• The author sees execution risk around costs and integration, but views the current price as not fully reflecting the cash flow potential of the combined healthcare business.

🐻 CVS Health Bear Case

Fair value: US$62.09 per share

Implied premium to this narrative: about 27% above fair value at the recent US$78.84 price

Revenue growth assumption: 7%

• This more cautious narrative points out that CVS Health already runs a complex mix of insurance, pharmacy benefits, retail and provider services, which may limit profit growth compared with some managed care peers.
• It highlights ongoing political risk around US healthcare reform and the possibility that new policies could pressure profitability or introduce volatility for the shares.
• It also flags challenges for the retail footprint and the risk that slower growth and operational headwinds could mean the current price sits above what this author views as a fair valuation.

If you want to see how other investors are framing the trade off between these two views and where your own expectations sit on that spectrum, See what the community is saying about CVS Health.

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com